Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 13/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23175929 | 0.88 | SMYD3 (0.47) | SMYD3CRBNMGLLHSD11B1 | |
| SCHEMBL23374101 | 0.84 | SMYD3 (0.47) | SMYD3CRBNHSD11B1 | |
| SCHEMBL29899587 | 0.82 | SMYD3 (0.53) | SMYD3CRBNMGLLHSD11B1 | |
| SCHEMBL13826111 | 0.81 | SMYD3 (0.54) | SMYD3CRBNMGLLHSD11B1 | |
| SCHEMBL16002937 | 0.76 | SMYD3 (0.52) | SMYD3CRBNMGLLHSD11B1 | |
| SCHEMBL23143574 | 0.75 | CRBN (0.71) | SMYD3CRBN | |
| SCHEMBL29899647 | 0.75 | CRBN (0.71) | SMYD3CRBN | |
| SCHEMBL29899605 | 0.74 | SMYD3 (0.58) | SMYD3CRBN | |
| SCHEMBL23175636 | 0.73 | SMYD3 (0.47) | SMYD3HSD11B1 | |
| SCHEMBL23143550 | 0.71 | SMYD3 (0.72) | SMYD3CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | UBQLN2, TXNRD1, TXNRD2 | SMYD3 4261/4885CRBN 342/4885OXTR 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.